Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer
See more from Petros Grivas
Interesting paper by Alec Zhu et al. looking at long term survival in pts with advanced urothelial cancer treated with FDA-approved ICI. We are achieving long-term survival in very few patients with advanced disease in clinical practice and we need to develop & validate biomarkers to help predict such outcomes. We also need new drugs & combos, e.g. IO+ADC, tested also in earlier (localized) stages.
PMID: 37043205